JP Patent
JP6934932B2 — アンドロゲン受容体アンタゴニストの固体医薬組成物
Assigned to レツク・フアーマシユーテイカルズ・デー・デー · Expires 2021-09-15 · 5y expired
What this patent protects
Patent listed against Uptravi.
Drugs covered by this patent
- Uptravi (SELEXIPAG) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.